1445. Deputy Ken O'Flynn asked the Minister for Health how many dedicated SCAN nurses are currently operating in each HSE region. [39822/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn .
3,835 questions match, newest first.
1446. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has established recommended staffing ratios or population benchmarks for SCAN services nationally. [39823/26]
1447. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE considers the provision of only two SCAN nurses sufficient for the Mid West population and crisis demand profile. [39824/26]
1448. Deputy Ken O'Flynn asked the Minister for Health when the two approved SCAN nurse posts for the Mid-West are expected to become operational. [39825/26]
1449. Deputy Ken O'Flynn asked the Minister for Health whether the posts have been advertised, filled, or remain vacant. [39826/26]
1450. Deputy Ken O'Flynn asked the Minister for Health whether any business case or service development proposal supporting the Mid-West SCAN expansion will be published. [39827/26]
1451. Deputy Ken O'Flynn asked the Minister for Health whether the HSE formally reviewed reimbursement, managed access, or pricing decisions relating to omaveloxolone (skyclarys) in France, Germany, Italy, Spain, Belgium, the Netherlands or the United Kingdom as part of the Irish reimbursement assessment process; and if she will provide details of any such comparative analysis undertaken. [39831/26]
1452. Deputy Ken O'Flynn asked the Minister for Health whether the National Centre for Pharmacoeconomics considered any international managed access agreements, risk-sharing agreements, conditional reimbursement models or outcomes-based reimbursement arrangements in respect of omaveloxolone (Skyclarys); and if she will provide details of the jurisdictions and models reviewed. [39832/26]
1453. Deputy Ken O'Flynn asked the Minister for Health whether any orphan-drug specific weighting, modified cost-effectiveness threshold, severity adjustment or rare disease reimbursement framework was applied in the assessment of omaveloxolone (skyclarys); and if she will make a statement on the matter. [39833/26]
1454. Deputy Ken O'Flynn asked the Minister for Health whether the assessment of omaveloxolone (skyclarys) included analysis of indirect societal costs associated with Friedreich's ataxia, including disability supports, caregiver burden, loss of educational participation, workforce impacts and long-term health service utilisation; and if she will provide details of the methodology used. [39834/26]
1455. Deputy Ken O'Flynn asked the Minister for Health whether Ireland currently operates a distinct reimbursement or pharmacoeconomic assessment pathway for orphan medicines or ultra-rare disease therapies; if so, to provide details of the framework and criteria applied; and if she will make a statement on the matter. [39835/26]
1456. Deputy Ken O'Flynn asked the Minister for Health the number of orphan or ultra-rare disease medicines which received a negative reimbursement recommendation from the National Centre for Pharmacoeconomics in each year since 2020; and the number subsequently approved for reimbursement following commercial negotiation or further review. [39836/26]
1457. Deputy Ken O'Flynn asked the Minister for Health the average period between European Medicines Agency authorisation and final reimbursement decision in Ireland for orphan medicines in each year since 2020; and how this compares with the EU average where such data is available. [39837/26]
1458. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has undertaken any comparative analysis of Ireland's orphan drug reimbursement timelines and approval rates against comparable European jurisdictions; and if she will provide details of any such analysis. [39838/26]
1459. Deputy Ken O'Flynn asked the Minister for Health whether patient organisations or rare disease advocacy groups were consulted or invited to make submissions during the reimbursement assessment process for omaveloxolone (skyclarys); and if she will provide details of the process involved. [39839/26]
1460. Deputy Ken O'Flynn asked the Minister for Health whether the HSE Drugs Group considered the progressive and degenerative nature of Friedreich's ataxia, including irreversible disease progression during reimbursement delays, in its consideration of omaveloxolone (Skyclarys); and if she will make a statement on the matter. [39840/26]
361. Deputy Ken O'Flynn asked the Minister for Health the number of presentations linked to domestic abuse recorded by emergency departments in each of the past five years and to date in 2026, in tabular form. [38588/26]
362. Deputy Ken O'Flynn asked the Minister for Health whether the HSE operates a national referral pathway for victims of domestic abuse presenting through primary care, emergency departments or mental health services. [38589/26]
363. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has undertaken any assessment of the mental health impact of domestic abuse on children residing in households where domestic abuse incidents have been reported. [38590/26]
947. Deputy Ken O'Flynn asked the Minister for Health whether any service-specific clinical governance framework exists in areas where the HSE has confirmed that no structured national data collection system is currently in place; and if she will provide copies of any such framework. [36532/26]
948. Deputy Ken O'Flynn asked the Minister for Health whether any formal risk assessment has been undertaken regarding the absence of national audit and monitoring systems in certain healthcare pathways; and if so, to provide the date and findings of such assessments. [36533/26]
949. Deputy Ken O'Flynn asked the Minister for Health whether the Department has received legal advice regarding the State's safeguarding and patient-safety obligations in circumstances where national audit mechanisms are absent. [36534/26]
950. Deputy Ken O'Flynn asked the Minister for Health how the HSE measures compliance with clinical governance standards in service areas where no national outcome dataset or audit infrastructure currently exists. [36535/26]
951. Deputy Ken O'Flynn asked the Minister for Health whether any external or independent review has been commissioned into the adequacy of governance and safeguarding arrangements in healthcare pathways where national data systems remain under development. [36536/26]
952. Deputy Ken O'Flynn asked the Minister for Health whether the Department considers reliance on general HSE governance structures, without dedicated national audit systems, sufficient to satisfy the State's obligations under patient-safety and safeguarding frameworks. [36537/26]